Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer

被引：47

作者：

Feng, Wan ^{[1
,2
]}

Zhang, Bin ^{[1
]}

Cai, Dawei ^{[2
]}

Zou, Xiaoping ^{[1
]}

机构：

[1] Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Gastroenterol, Nanjing 210008, Jiangsu, Peoples R China

[2] Nanjing Univ, Sch Med, Nanjing 210008, Jiangsu, Peoples R China

来源：

CANCER LETTERS | 2014年 / 347卷 / 02期

关键词：

Histone deacetylases; HDAC inhibitors; Pancreatic cancer; Combination therapy; SUBEROYLANILIDE HYDROXAMIC ACID; TARGETING TUMOR ANGIOGENESIS; PHASE-III TRIAL; TRICHOSTATIN-A; MESENCHYMAL TRANSITION; EXPRESSION PROFILE; INDUCED APOPTOSIS; CELL-DEATH; IN-VITRO; GEMCITABINE;

D O I：

10.1016/j.canlet.2014.02.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pancreatic cancer is a devastating disease with a dismal prognosis. Surgical resection is the only curative option but is heavily hampered by delayed diagnosis. Due to few therapeutic treatments available, novel and efficacious therapy is urgently needed. Histone deacetylase inhibitors (HDACIs) are emerging as a prominent class of therapeutic agents for pancreatic cancer and have exhibited significant anticancer potential with negligible toxicity in preclinical studies. Clinical evaluations of HDACIs are currently underway. HDACIs as monotherapy in solid tumors have proven less effective than hematological malignancies, the combination of HDACIs with other anticancer agents have been assessed for advanced pancreatic cancer. In this review, we describe the molecular mechanism underpin the anticancer effect of HDACIs in pancreatic cancer and summarize the recent advances in the rationale for the combination strategies incorporating HDACIs. In addition, we discuss the importance of identifying predictors of response to HDACI-based therapy. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

引用

页码：183 / 190

页数：8

共 109 条

[11] Hypoxia and angiogenesis: regulation of hypoxia-inducible factors via novel binding factors [J].

Chen, Li ;

Endler, Alexander ;

Shibasaki, Futoshi .

EXPERIMENTAL AND MOLECULAR MEDICINE, 2009, 41 (12) :849-857

[12]

Chien W., 2013, Mol Carcinog

[13] Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions [J].

Choudhary, Chunaram ;

Kumar, Chanchal ;

Gnad, Florian ;

Nielsen, Michael L. ;

Rehman, Michael ;

Walther, Tobias C. ;

Olsen, Jesper V. ;

Mann, Matthias .

SCIENCE, 2009, 325 (5942) :834-840

[14] Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer [J].

Chun, Stephen G. ;

Zhou, Weiqiang ;

Yee, Nelson S. .

CANCER BIOLOGY & THERAPY, 2009, 8 (14) :1328-1339

[15] Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study [J].

Colucci, Giuseppe ;

Labianca, Roberto ;

Di Costanzo, Francesco ;

Gebbia, Vittorio ;

Carteni, Giacomo ;

Massidda, Bruno ;

Dapretto, Elisa ;

Manzione, Luigi ;

Piazza, Elena ;

Sannicolo, Mirella ;

Ciaparrone, Marco ;

Cavanna, Luigi ;

Giuliani, Francesco ;

Maiello, Evaristo ;

Testa, Antonio ;

Pederzoli, Paolo ;

Falconi, Massimo ;

Gallo, Ciro ;

Di Maio, Massimo ;

Perrone, Francesco .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (10) :1645-1651

[16] Phase I Pharmacokineitic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors [J].

de Bono, Johann S. ;

Kristeleit, Rebecca ;

Tolcher, Anthony ;

Fong, Peter ;

Pacey, Simon ;

Karavasilis, Vasilios ;

Mita, Monica ;

Shaw, Heather ;

Workman, Paul ;

Kaye, Stan ;

Rowinsky, Eric K. ;

Aherne, Wynne ;

Atadja, Peter ;

Scott, Jeffrey W. ;

Patnaik, Amita .

CLINICAL CANCER RESEARCH, 2008, 14 (20) :6663-6673

[17] HDAC modulation and cell death in the clinic [J].

Dell'Aversana, Carmela ;

Lepore, Ilaria ;

Altucci, Lucia .

EXPERIMENTAL CELL RESEARCH, 2012, 318 (11) :1229-1244

[18] Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC) [J].

Di Costanzo, F ;

Carlini, P ;

Doni, L ;

Massidda, B ;

Mattioli, R ;

Iop, A ;

Barletta, E ;

Moscetti, L ;

Recchia, F ;

Tralongo, P ;

Gasperoni, S .

BRITISH JOURNAL OF CANCER, 2005, 93 (02) :185-189

[19] Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine [J].

Donadelli, Massimo ;

Costanzo, Chiara ;

Beghelli, Stefania ;

Scupoli, Maria Teresa ;

Dandrea, Mario ;

Bonora, Antonio ;

Piacentini, Paolo ;

Budillon, Alfredo ;

Caraglia, Michele ;

Scarpa, Aldo ;

Palmieri, Marta .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2007, 1773 (07) :1095-1106

[20]

Doss H., 2008, J CLIN ONCOL, V26, P25

← 1 2 3 4 5 6 7 8 9 10 →